To visit the Global Nebido® website, please choose from the options below:
In his presentation “The role of TRT in the management of hypogonadism: Dispelling the myths”, Dr. Geoffrey Hackett looks at safety concerns in connection with testosterone replacement therapy (TRT).
Effects of TRT on various parameters of cardiometabolic health are shown, and current evidence regarding prostate safety is presented.
Professor Geoff Hackett Aston University & University Hospitals Birmingham NHS Foundation Trust
Professor Ridwan Shabsigh
Professor Siegfried Meryn
Professor Myles Spar
Professor Joel Heidelbaugh
Copyright © 2021, Bayer AG
This website contains information on Nebido (testosterone undecanoate) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission.
This website is intended to provide information to an international audience outside Austria, France, Germany, Hungary, Ireland, the Middle East, the Philippines, Thailand, the UK, and the USA.
Page last modified 01/04/2021
PP-NEB-ALL-0222-1 April 2021